Results 1 to 10 of about 2,233 (106)

Acute graft versus host disease [PDF]

Orphanet Journal of Rare Diseases, 2007
Acute graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial cells after an inflammatory cascade that begins
Vogelsang Georgia B, Jacobsohn David A
doaj   +3 more sources

Acute graft-versus-host disease

Journal of Bone Marrow Transplantation and Cellular Therapy
Despite current advances in graft-versus-host disease (GvHD) prophylaxis, it remains one of the leading causes of morbidity and mortality after hematopoietic cell transplantation (HCT).
Adriana Mello Rodrigues, Rita de Cassia Barbosa da Silva Tavares, Carla Nolasco Monteiro Breviglieri, Marcia de Matos Silva, Roseane Vasconcelos Gouveia, Virgínio Climaco de Araújo Fernandes Junior, Luis Fernando Bouzas   +6 more
doaj   +5 more sources

Intestinal acute graft versus host disease

Journal of the Belgian Society of Radiology, 2010
Background: We present a case of a 23-year-old man having drug addiction. He is managed by the department of hematology for an idiopathic medullar aplasia. Two months before his admission, he was treated with bone marrow transplantation. During follow-up,
E Danse, C Dragean, C Rovani
doaj   +5 more sources

Oral acute graft‐versus‐host disease

eJHaem
Oral acute graft‐versus‐host disease (aGVHD) is rare and with no diagnostic criteria. We report a case of oral aGVHD with three clinical phases. A self‐limited prodrome of largely subjective oral symptoms was followed by concurrent oral and upper ...
Farzad Teymouri, Gale Sebastian, Hakan Gem, Samuel S. Minot, Armin Rashidi   +4 more
doaj   +3 more sources

Acute Graft-versus-Host Disease [PDF]

New England Journal of Medicine, 2018
AbstractAcute graft-versus-host disease (GvHD) remains a major course of short term (100 days and 1 yr) mortality and morbidity after allogeneic stem cell transplantation. The pathophysiology of GvHD is described as a 3 step process starting with initial tissue damage by conditioning followed by host antigen presenting cell activation by damage and ...
Robert, Zeiser, Bruce R, Blazar
  +6 more sources

The Immunopathophysiology of Acute Graft‐Versus‐Host‐Disease [PDF]

STEM CELLS, 1996
The major complication after allogeneic bone marrow transplantation (BMT) is the development of graft-versus-host-disease (GVHD). This disease is initiated during the conditioning of the recipient, when host tissues are damaged. During the afferent phase of the disease, alloreactive donor T cells recognize foreign major and minor histocompatibility ...
J L, Ferrara, K R, Cooke, L, Pan, W, Krenger   +3 more
openaire   +2 more sources

When donor T cells attack: The curious case of liver transplant-associated acute graft-versus-host-disease

Science Progress, 2022
Graft versus host disease is a rare but deadly complication of solid organ transplant. Clinical features of graft-versus-host-disease are non-specific, which may lead to delayed diagnosis as more common conditions including infections or drug reactions ...
Max Deschner, Donald J. Bastin, Ziad Solh, Karen Bosma, Wael Haddara, Ping Yang, Robert Broadbent, Aaron Haig, Jonathan Keow, Mayur Brahmania, Anargyros Xenocostas, Uday Deotare   +11 more
doaj   +1 more source

Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review [PDF]

Anais Brasileiros de Dermatologia, 2016
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplants (allo-HSCT) associated with significant morbidity and mortality. The earliest and most common manifestation is cutaneous graft-versus-host disease.
Cesar Daniel Villarreal Villarreal, Julio Cesar Salas Alanis, Jose Carlos Jaime Pérez, Jorge Ocampo Candiani   +3 more
doaj   +1 more source

Acute Graft-Versus-Host Disease

Immunotherapy, 2011
1419 ISSN 1750-743X 10.2217/IMT.11.133 © 2011 Future Medicine Ltd Immunotherapy (2011) 3(12), 1419–1422 “First-line treatment of aGvHD, with methylprednisolone 2 mg/kg/day, is effective in over 50% of patients, produces durable responses but only in one out of three patients. Steroid-refractory or steroid-dependent GvHD patients are offered second-line
Sujay Khandpur, MaheshK Kumawat
  +5 more sources

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated

Haematologica, 2018
Upper gastrointestinal acute graft-versus-host disease is reported in approximately 30% of hematopoietic stem cell transplant recipients developing acute graft-versus-host disease.
Sarah Nikiforow, Tao Wang, Michael Hemmer, Stephen Spellman, Görgün Akpek, Joseph H. Antin, Sung Won Choi, Yoshihiro Inamoto, Hanna J. Khoury, Margaret MacMillan, David I. Marks, Ken Meehan, Hideki Nakasone, Taiga Nishihori, Richard Olsson, Sophie Paczesny, Donna Przepiorka, Vijay Reddy, Ran Reshef, Hélène Schoemans, Ned Waller, Daniel Weisdorf, Baldeep Wirk, Mary Horowitz, Amin Alousi, Daniel Couriel, Joseph Pidala, Mukta Arora, Corey Cutler   +28 more
doaj   +1 more source